MIRA Pharmaceutical Shares Are Trading Higher After the Company's New Preclinical Data Showed That Ketamir-2 Achieved 60% Greater Efficacy Than the FDA-approved Gabapentin in Reducing Chemotherapy-induced Pain.
MIRA Pharmaceutical Shares Are Trading Higher After the Company's New Preclinical Data Showed That Ketamir-2 Achieved 60% Greater Efficacy Than the FDA-approved Gabapentin in Reducing Chemotherapy-induced Pain.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated